The crystal and molecular structure of the complexes K2[Pd(bs-α-alaNO)2]·3.5H2O 1, [Pd(tsglyNO)(bipy)]2 and [Pd(bs-β-alaNO)(bipy)]·H2O 3 were determined by X-ray diffraction (bs-α-alaNO = phenylsulfonyl-DL-α-alaninate dianion; tsglyNO =N-p-tolylsulfonylglycinate dianion; bipy = 2,2′-bipyridine; bs-β-alaNO =N-phenylsulfonyl-β-alaninate dianion). Compound 1 crystallizes in the triclinic space group P with a= 13.457(3), b= 9.855(2), c= 10.739(2)Å, α= 104.0(1), β= 100.8(1), γ= 78.0(1)°, Z= 2. The Pd atom has a square-planar-environment, being trans co-ordinated by two centrosymmetrically related ts-α-alaNO dianions acting in a bidentate manner through one carboxylic oxygen and the deprotonated sulfonamide nitrogen. Compound 2 crystallizes in the monoclinic space group P21/c with a= 1 2.210(1), b= 6.897(3), c= 21.449(2)Å, β= 95.55(1)°, Z= 4. Compound 3 crystallizes in the monoclinic space group Pc, with a= 8.320(5), b= 14.403(3), c= 8.477(4)Å, β= 101.81 (4), Z= 2. Both complexes contain a Pd2+ ion co-ordinated to the N atoms of the bipy molecule and to the deprotonated sulfonamide nitrogen and one carboxylic oxygen of the amino acid molecule in a square-planar geometry. The amino acid dianion forms a five-membered glycine-like chelate ring in 1 and 2, and a six-membered ring in 3. Infrared data are also discussed and compared with those of the free ligands and the corresponding binary complexes.
No takes yet. Share an insight, caveat, or question.
Corradi et al. (1994) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: